JAK2-IN-7

TargetMol
Product Code: TAR-T35900
Supplier: TargetMol
CodeSizePrice
TAR-T35900-1mg1mg£277.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T35900-5mg5mg£584.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T35900-10mg10mg£785.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T35900-25mg25mg£1,171.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T35900-50mg50mg£1,540.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T35900-100mg100mg£2,062.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
JAK2-IN-7 is a selective JAK2 inhibitor with IC50s of 3, 11.7, and 41 nM for JAK2, SET-2, and Ba/F3V617F cells, respectively. JAK2-IN-7 possesses >14-fold selectivity over JAK1, JAK3, FLT3. JAK2-IN-7 stimulates cell cycle arrest in the G0/G1 phase and induces tumor cellapoptosis. Antitumor activities[1].
CAS:
2593402-36-7
Formula:
C26H33N7O
Molecular Weight:
459.59
Pathway:
Stem Cells; Chromatin/Epigenetic; Angiogenesis; JAK/STAT signaling
Purity:
0.98
SMILES:
CC(C)n1ncc(-c2c(C)cnc(Nc3cc(CCN(C4)C(/C=C/CN(C)C)=O)c4cc3)n2)c1
Target:
JAK

References

Yang T, et al. N-(Pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms [published online ahead of print, 2020 Nov 30]. J Med Chem. 2020;10.1021/acs.jmedchem.0c01488.